


## Abstract of the Disclosure

A treatment for glomerulonephritis with  $(\pm)$ -1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate.

This invention relates to prophylactic or therapeutic drug for diabetic nephropathy or glomerulonephritis, comprising, as an active ingredient, a compound or salt thereof represented by general formula (I)

(I)



wherein  $R^1$  stands for H or an optionally substituted hydrocarbon residue;  $R^2$  stands for an optionally esterified carboxyl group;  $R^3$  stands for a group actually or potentially capable of forming an anion; X shows that the phenylene and phenyl groups bind to each other directly or through a spacer having an atomic chain length of two or less; n stands for 1 or 2; ring A stands for a benzene ring having an optional substituent in addition to  $R^2$ ; Y stands for a bond, —O—, —S(O)<sub>m</sub>— (wherein m stands for 0, 1 or 2), or —N( $R^4$ )— (wherein  $R^4$  stands for H or an optionally substituted alkyl group).